EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment

EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment

Abstract EZH2 is mutated in nearly 25% of follicular lymphoma (FL) cases. Little is known about how EZH2 affects patients’ response to therapy. In this context, the aim of this study was to retrospectively analyze the frequency of mutations in EZH2 at diagnosis in tissue and ctDNA in patients with F...

Full description

Bibliographic Details
Main Authors: C. Martínez-Laperche, L. Sanz-Villanueva, F. J. Díaz Crespo, P. Muñiz, R. Martín Rojas, D. Carbonell, M. Chicano, J. Suárez-González, J. Menárguez, M. Kwon, J. L. Diez Martín, I. Buño, M. Bastos Oreiro
Format: Article
Language:English
Published: BMC 2022-09-01
Series:BMC Cancer
Subjects:
Follicular lymphoma
EZH2
R-Bendamustine
R-CHOP
Online Access:https://doi.org/10.1186/s12885-022-10070-z

Similar Items

Similar Items